Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer deaths among men in the United States. It is a critical public health problem and remains incurable in the metastatic setting with mortality that usually occurs as a result of castration-resistant disease.
This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry.
Part I describes the role of androgens and androgen deprivation therapy in prostate cancer and the several types of hormone therapy used to treat advanced prostate cancer, including luteinizing hormone-releasing hormone agonists and antagonists, and anti-androgens. Androgen receptor biology and the pharmacogenetics of the androgen metabolic pathway are also presented.
Part II discusses the role of chemotherapy in prostate cancer including standard and investigational approaches as well as the clinical pharmacology and pharmacogenetics of these agents.
Part III introduces the concept of angiogenesis in prostate cancer by discussing the principles of anti-angiogenic therapy, investigational angiogenesis inhibitors, and the pharmacogenetics of angiogenesis.
Part IV focuses on the pathophysiology of prostate cancer bone metastasis and the agents used at this stage of the disease process. Part V continues on to describe the role of immunotherapy for advanced prostate cancer including immunotherapeutics and vaccine approaches.
In Part VI, chemoprevention strategies for prostate cancer are discussed. The last section of the book, Part VII, looks at the overall drug and technological development efforts and challenges in prostate cancer.
As such, this book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer detailing knowledge of both conventional and emerging drug therapies. The chapters describe state-of-the-art information that will be appropriate for medical students, physicians in training, physicians, scientists, and members of the pharmaceutical industry. As advances in understanding the biology of prostate cancer and the mechanisms of castration-resistant disease continue over the next decade, novel drug discovery and development efforts will translate into emerging treatment paradigms in the therapeutic management of prostate cancer.
Book Details
This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry.
Part I describes the role of androgens and androgen deprivation therapy in prostate cancer and the several types of hormone therapy used to treat advanced prostate cancer, including luteinizing hormone-releasing hormone agonists and antagonists, and anti-androgens. Androgen receptor biology and the pharmacogenetics of the androgen metabolic pathway are also presented.
Part II discusses the role of chemotherapy in prostate cancer including standard and investigational approaches as well as the clinical pharmacology and pharmacogenetics of these agents.
Part III introduces the concept of angiogenesis in prostate cancer by discussing the principles of anti-angiogenic therapy, investigational angiogenesis inhibitors, and the pharmacogenetics of angiogenesis.
Part IV focuses on the pathophysiology of prostate cancer bone metastasis and the agents used at this stage of the disease process. Part V continues on to describe the role of immunotherapy for advanced prostate cancer including immunotherapeutics and vaccine approaches.
In Part VI, chemoprevention strategies for prostate cancer are discussed. The last section of the book, Part VII, looks at the overall drug and technological development efforts and challenges in prostate cancer.
As such, this book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer detailing knowledge of both conventional and emerging drug therapies. The chapters describe state-of-the-art information that will be appropriate for medical students, physicians in training, physicians, scientists, and members of the pharmaceutical industry. As advances in understanding the biology of prostate cancer and the mechanisms of castration-resistant disease continue over the next decade, novel drug discovery and development efforts will translate into emerging treatment paradigms in the therapeutic management of prostate cancer.
Book Details
- Editor: William D. Figg, Cindy H. Chau, and Eric J. Small
- Hardcover: 428 pages
- Publisher: Springer; 1st Edition (September 17, 2010)
- Language: English
- ISBN-10: 1603278311
- ISBN-13: 978-1603278317